摘要
目的:分析89锶治疗转移性骨肿瘤的临床疗效及其安全性。方法:42例转移性骨肿瘤患者接受了89锶治疗。治疗后定期测定血常规、血生化等指标,随访时间3个月以上。对患者骨痛缓解情况、不良反应和血液学、肝肾功能变化进行观察和评价。结果:42例中有效35例,总有效率83.3%,起效时间2—20 d,缓解持续时间3—14个月。毒性反应主要有轻度可逆性骨髓抑制,血液学毒性小于Ⅱ级。无过敏反应及其他特殊不良反应。对肝肾功能无明显影响。结论:89锶对于转移性骨肿瘤所致的剧烈疼痛有良好的止痛效果,毒副作用小,是提高患者的生存质量的一种有效、安全的治疗方法。
Objective: To evaluate the efficacy of strontium dichloride in the treatment of ostalgia from metastic bone tumour. Method: 42 patients with the ostalgia from metastatic bone tumour were treated with strontium dichloride. The immediate adverse reactions were observed. Their bone pain score, blood routine, liver and renal function were followed up. Result: The clinical significant relief of ostalgia could be observed in 83. 3% (35 cases) , no hypersensitive and other ADRs were observed. The relieving time of ostalgia lasted 3-14 months. The toxic reaction mainly had bone marrow inhibition. The blood toxicity was less than grade Ⅱ. No 1 esions to liver and renal functions were observed. Conclusion: 89Sr was safe and effective in the treatment from ostalgia of metastatic bone tumour. It was helpful for improving patients'life quality.
出处
《中国药师》
CAS
2005年第5期408-409,共2页
China Pharmacist
